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Summary. Background: Despite growing use, peripherally
inserted central catheters (PICCs) are associated with risk
of deep vein thrombosis (DVT). We designed a study to
determine patient, provider and device factors associated
with this outcome. Methods: This was a retrospective
cohort study of adults who underwent PICC placement
between 1 June 2009 to 30 June 2012. Symptomatic
PICC-associated DVT was confirmed by ultrasound.
Because PICCs are also recognized risk factors for lower-
extremity DVT, lower-extremity DVT occurring while the
PICC was in situ was included. Multivariable logistic and
Cox-proportional hazards regression models were fit to
examine the association between covariates specified a pri-
ori and PICC-DVT. Odds ratios (ORs) and hazard ratios
(HRs) with corresponding 95% confidence intervals (CIs)
were generated. Results: Of 966 unique PICC placements,
33 patients developed symptomatic PICC-associated DVT
and 9 developed lower-extremity DVT, accounting for 42
thrombotic events. On bivariate analysis, recent diagnosis
of cancer, interventional radiology placement, chemother-
apy administration, number of lumens and PICC-gauge
were associated with PICC-DVT. Following multivariable
adjustment, recent cancer diagnosis (OR 1.95 [95% CI
1.01–3.76]) and PICC gauge (HR 2.21 [95%CI 1.04–4.70]
and HR 3.56 [95%CI 1.31–9.66] for 5-Fr and 6-Fr
PICCs, respectively) remained associated with thrombosis.
Conclusions: Recent diagnosis of cancer and PICC gauge
are associated with PICC-DVT. These findings have
important clinical ramifications and suggest that place-
ment of large gauge PICCs or PICCs in patients with
cancer may provoke thrombosis. Improved policies and
procedural oversights in these areas appear necessary to
prevent PICC-DVT.
Keywords: central venous catheter thrombosis; central
venous catheters; deep vein thrombosis; peripheral venous
catheterization; upper extremity deep vein thrombosis;
venous thromboembolism.
Introduction
The use of peripherally inserted central catheters (PICCs)
has grown rapidly in the United States [1]. Because these
devices are inserted in the arm and avoid many of the iat-
rogenic, mechanical complications associated with central
venous catheter insertion in the neck or chest, they are
often considered safer than their traditional counterparts.
Furthermore, with the advent of vascular access nursing
teams, who provide high rates of insertion success and
evidence-based insertion and maintenance, PICCs have
become more accessible to hospitals across the country,
often serving as a bridge for intravenous therapies from
the inpatient to the outpatient setting [2].
Despite these advantages, PICCs are increasingly asso-
ciated with deep vein thrombosis of the arm (PICC-
DVT), a complication that has important consequences
[3,4]. For example, PICC-DVT often leads to interrup-
tions in treatment, creating a conundrum for providers
who rely on these devices for venous access, while increas-
ing length of stay and cost [5.] This adverse event also
leads to significant scarring and obliteration of upper
extremity deep veins, impairing venous return and subse-
quent venous access. Thrombosis associated with PICCs
often resolves with residual venous stenosis of the upper
extremities [6] and has been recognized as a key predictor
of arteriovenous graft failure in patients on hemodialysis
[7]. In its most severe form, PICC-DVT may cause pul-
monary embolism, an outcome that is especially frequent
in critically ill and cancer populations [3]. Finally, the
thrombogenic burden associated with PICCs is known to
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extend beyond veins of the arm, as PICCs are increas-
ingly recognized as one of the strongest risk factors for
in-hospital, lower-extremity DVT [8,9]. Given all of these
risks, both the Society of General Internal Medicine and
the American Society of Nephrology have suggested cau-
tion with the use of PICCs in their national Choosing
Wisely initiatives [10,11].
To better inform clinical practice and reduce the risk of
PICC-DVT, factors associated with this adverse event
must be identified. Early studies have demonstrated that
a number of modifiable and non-modifiable factors are
associated with PICC thrombosis [5,12–15]. However,
there remains a paucity of data regarding which of these
may be targeted to reduce venous thromboembolism.
Therefore, we conducted a retrospective study to examine
patterns, incidence, timing and predictors of PICC-DVT.
In accordance with a previously published framework
[16], we hypothesized that specific patient-, provider-, and
device-related characteristics would be associated with
PICC-DVT. We were most interested in factors that
could be modified to reduce the risk of thrombosis associ-
ated with these devices.
Patients and methods
Using records obtained from our vascular access nursing
team, we assembled a cohort of consecutive, adult, hospi-
talized patients who underwent insertion of a PICC
between 1 June 2009 and 30 June 2012 at our 145-bed,
academic Veterans Affairs (VA) Medical Center. Clinical
data, such as indication for insertion, number of insertion
attempts, vein and arm of insertion, and details regarding
the type of PICC (lumens, gauge, coating), were directly
abstracted from electronic medical records. Information
regarding patient co-morbidities, medications and dos-
ages, disposition and admission/discharge diagnoses was
obtained from administrative datasets. Because data
regarding device details and insertion were missing from
patients who had PICCs placed at another institution,
such patients were excluded from our study.
PICC-DVT was identified through a combination of
vascular access nursing records, ICD-9 codes and chart
review. DVTs were classified as being PICC-associated
when B-mode or Doppler ultrasound revealed the pres-
ence of thrombus in the deep veins of the arm (brachial,
axillary and subclavian veins) while a PICC was in situ.
In all cases, testing was performed in the presence of clin-
ical signs or symptoms (e.g. arm pain, swelling or short-
ness of breath); further evaluation for extension in the
superior vena cava or pulmonary embolism was only per-
formed if symptoms suggest the same. Difficulties flushing
the line prompted vascular access nursing referral for a
‘declot’ evaluation, but only led to ultrasound testing if
clinical signs suggestive of thrombosis were present.
Because the presence of a PICC is a known risk factor
for lower-extremity DVT [8,9,17], we also included
thrombosis involving the deep veins of the leg if it
occurred when the PICC was in place. Patients were fol-
lowed until the PICC was removed (regardless of whether
this occurred in the hospital or the home setting), as our
vascular access team is responsible for all device remo-
vals. Only patients with PICCs for whom complete data
were available, from insertion to removal, were included
in the final cohort.
PICC insertion and care
All PICC insertions by our vascular access nursing team
and interventional radiologists employ standard aseptic
precautions. Portable ultrasonography is routinely per-
formed prior to PICC placement to identify a suitable
vein for insertion. All PICCs are placed in veins that are
deemed to have an appropriate size and location (above
the elbow and at least twice the size of the maximal PICC
diameter). Should bedside PICC placement prove difficult
(e.g. coiling or kinking of the catheter despite several
attempts) or technically unfeasible (e.g. no visible veins
for insertion), patients are referred to interventional radi-
ology for PICC placement. Following insertion, PICC-tip
position at the cavoatrial junction is verified by chest x-
ray or fluoroscopy, with subsequent adjustments made
according to radiologist interpretation of catheter-tip
position. No PICCs are used prior to verification of cen-
tral termination of the tip. Surveillance imaging for incor-
rect position or thrombosis is not performed at our
facility.
Routine device and site checks are performed weekly by
the vascular access team or earlier if malfunction occurs.
All PICC lumens are flushed with 10 mL normal saline and
5 mL heparin daily according to a defined maintenance
protocol. In the event of luminal occlusion (failure to flush
or withdraw from the PICC), 2 mg mL1 of tissue plas-
minogen-activator is instilled in each lumen to ‘declot’ the
device. At our hospital, patients with PICCs do not receive
pharmacologic DVT prophylaxis on account of the device
itself, but most patients tend to receive prophylaxis due to
coexisting medical co-morbidities.
Variables and definitions
Duration of PICC use was calculated in days by subtract-
ing the date of removal from the date of PICC placement,
whereas time to DVT was calculated by subtracting the
date of the positive ultrasound study from the date of
PICC insertion. Patients with recent diagnosis of cancer
were identified by searching for ICD9-specific codes for
cancer in the inpatient or outpatient setting in the
6 months prior to the PICC-related admission using a vali-
dated algorithmic approach [18]. Similarly, active chemo-
therapy was flagged when patients received an oral or
intravenous chemotherapeutic agent during, or 6 months
prior to, PICC insertion. We defined ICU status as includ-
Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
848 V. Chopra et al
ing patients who received care in any ICU setting at any
point during hospitalization. PICC dislodgements were
defined as accidental removal of the PICC by either the
patient or provider. Antibiotic use was defined as adminis-
tration of any oral or intravenous antimicrobial within
30 days of PICC insertion. We included chemotherapy,
and steroid use if any of these events occurred within
6 months of PICC placement. Surgery was defined as any
operation lasting ≥ 1 h during the index admission (before
the PICC was put in place, on the same day as PICC inser-
tion or while the PICC was in situ).
Statistical analysis
The unit of analysis was PICC insertion. The study popula-
tion was first characterized using descriptive statistics.
Bivariate logistic regression was used to estimate unad-
justed odds ratios (ORs) and 95% confidence intervals
(CIs) for the association between all risk factors and PICC-
DVT. We used our previously published conceptual model
of predictors of PICC complications to structure our multi-
variable analytic approach [16]. In brief, this model was
derived by systematically synthesizing the published evi-
dence and identified the risk of PICC-related complications
as being related to patient-, provider-, and device-related
characteristics (Fig. 1). Because we were specifically inter-
ested in time-to-DVT in addition to standard predictors,
we constructed multivariable logistic regression and Cox
proportional hazards regression models to estimate ORs
and hazard ratios (HRs) with 95% CIs, respectively.
Adjustment for baseline characteristics was made on scien-
tific grounds in all models. Standard errors were adjusted
to account for within-patient clustering of observations
(e.g. patients with multiple lines). Covariate correlations
and variance inflation factors were assessed to ensure
absence of collinearity. SAS for Windows (Version 9.3,
SAS Inc., Cary, NC, USA) and Stata MP SE (StataCorp
Version 13, College Station, TX, USA) were used for
analyses. All statistical tests were two-tailed; P < 0.05 was
considered statistically significant.
The Institutional Review Board of the Veterans Affairs
Ann Arbor Healthcare System granted ethical and regula-
tory approval for the study.
Results
Between 1 June 2009 and 30 June 2012, 1241 PICCs were
inserted at our academic VA medical center. Of these 1241
PICCs: 71 were removed without a documented removal
date; 46 had no matching inpatient visits; and 158 had no
matching administrative data. Therefore, our final study
cohort included 966 PICCs that were inserted in 747 unique
patients, accounting for a total of 26 887 catheter days
(Fig. 2). The majority of patients who underwent insertion
were male (98%), with a median duration of PICC use of
21 days (95% CI, 19–23 days). Most PICCs were placed
by vascular access nurses (85%, n = 823); only 15%
(n = 143) were placed by interventional radiology when
bedside insertion was not successful or appropriate. Over
one-third of our inpatient cohort (n = 301; 40%) had a
cancer diagnosis in the 6 months prior to PICC insertion;
145 were receiving active chemotherapy at the time of hos-
pitalization (Tables 1 and 2). Over 95% (n = 713) of
included patients were prescribed pharmacologic DVT pro-
phylaxis with either subcutaneous heparin or daily enoxap-
arin while the PICC was in place.
The most common indications for PICC insertion
included: long-term antibiotic administration (52%,
n = 503), venous access (21%, n = 201), total parenteral
nutrition (16%, n = 155) and delivery of chemotherapy
(11%, n = 107). With respect to PICC characteristics,
almost half of all PICCs inserted were single-lumen
devices (48%, n = 459) and many were POWER-PICCs
(52%, n = 500), specialized devices capable of withstand-
ing high-pressure injections for radiographic studies.
While the majority of PICCs were placed in patients on
medical or surgical units, 171 (18%) were inserted in
intensive care unit patients. PICCs were most commonly
Patient factors Device factors
Provider factors
Indication for insertion
Number of adjustments
Pharmacologic prophylaxis
Nature of PICC operator
Early removal of PICCs
Flushing protocol
Type of PICC
Number of lumens
PICC gauge
Central tip location
Catheter coating
Valve/non-valved
POWER PICC
Prior DVT
Critically III/ICU
Surgery ≥ 1 h 
Cancer
Arm of insertion
Vein of insertion
Prior VTE
Fig. 1. Conceptual model for PICC-Related Deep Vein Thrombosis.
Patients identified as having received a PICC between January 2009–October 2012
N = 1241
N = 71
N = 46
N = 158
N = 966
No recorded removal date
No matching inpatient visit
No matching administrative data
Eligible patients included in the analysis
Fig. 2. Flow diagram illustrating generation of final study cohort.
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inserted in the basilic vein (77%, n = 742) and in the right
arm (70%, n = 674).
Among the 966 included PICCs, 33 (3.4%) were associ-
ated with PICC-DVT and 9 (1%) were associated with
lower extremity DVT, accounting for a total of 42 symp-
tomatic thrombotic events (4.3%). The mean time to
PICC-DVT was 16.5 days vs. 10.7 days for lower-extrem-
ity DVT with a PICC in situ. Most patients who experi-
enced PICC-DVT did so in the context of prolonged
hospitalization (average length of stay 12 days), including
a significant number of ICU days (6.5 days). Exactly half
(n = 21) of PICC-DVT patients had a recent cancer diag-
nosis when thrombosis occurred, and many were receiving
chemotherapy at the time (Table 2). Despite reports of an
association between thrombosis and infection [19], no
patient with PICC-DVT experienced a preceding central
line-associated bloodstream infection in our study. With
respect to location of thrombosis, PICC-DVT more com-
monly involved the axillary and subclavian veins, though
many were associated with thrombosis at ≥ 1 site.
On bivariate analysis, a number of patient-, provider-
and device-related characteristics, including recent cancer
(OR 2.30 [95% CI 1.12–4.41]), interventional radiology
placement (OR 2.42 [1.24–4.73]), chemotherapy infusion
(4.11 [1.78–9.47]), number of lumens (OR 2.51 [1.22–5.15]
and OR 3.32 [1.24–8.84] for double- and triple-lumen
PICCs, respectively) and PICC gauge (OR 2.28 [1.11–
4.68] and OR 2.74 [1.03–7.29] for 5Fr and 6Fr PICCs,
respectively) were associated with PICC-DVT. We did
not observe an association between vein (cephalic vs. all
others) or arm (right vs. left) of insertion with PICC-
DVT. POWER-PICCs did not confer a greater risk of
thrombosis compared with non-POWER devices in
bivariate analysis (Table 3).
In our multivariable logistic regression and Cox propor-
tional hazards regression models, only a diagnosis of recent
cancer (cancer diagnosis in the 6-months prior to PICC pla-
cement) (OR 1.95 [1.01–3.76]) and PICC gauge (HR 2.21
[95% CI 1.04–4.70] and HR 3.56 [95% CI 1.31–9.66] for 5-
Fr and 6-Fr PICCs, respectively) remained associated with
PICC- DVT (Table 4). Importantly, the influence of gauge
on thrombosis was noted to be time dependent, with an ear-
Table 1 Characteristics of upper and lower extremity thrombosis in
patients with PICC
Variable
PICC-DVT
(N = 33)
LE DVT
(N = 9)
No DVT
(N = 924)
Age 64.2  8.0 64.4  3.9 65.5  10.3
Male gender 32 (97.0) 9 (100) 897 (97.1)
Acute LOS 12.0  11.7 26.3  23.1 11.0  11.9
ICU LOS 6.5  12.4 2.6  4.8 5.6  16.4
Cancer (6 months) 16 (48.5) 5 (55.6) 280 (30.3)
Prior DVT 1 (3.0) 1 (11.1) 31 (3.4)
Prior surgery (> 1 h) 12 (36.4) 0 (0) 267 (28.9)
Prior PICC use 0.24  0.44 0.67  1.12 0.27  0.59
Anticoagulant use
Heparin 27 (81.8%) 7 (77.8%) 679 (73%)
Enoxaparin 11 (33.3%) 4 (44.4%) 124 (13%)
Warfarin 7 (21.2%) 0 (0%) 112 (12%)
CLABSI 0 (0%) 1 (11.1%) 57 (6.2%)
Mortality 4 (12.1%) 0 (0%) 54 (5.8%)
No. of insertion
attempts
1.18  0.53 1.78  0.83 1.25  0.64
Adjustments during
insertion
Yes 6 (18.2) 0 (0) 196 (21.2)
Number of
adjustments
0.18  0.39 0.0  0.0 0.27  0.58
Dislodgements
Yes 0 (0) 0 (0) 46 (5.0)
Duration of
PICC use (days)
37.3  69.7 28.2  18.6 27.5  25.9
Operator
IR 9 (27.3) 3 (33.3) 131 (14.2)
Nursing 24 (72.7) 6 (66.7) 793 (85.8)
Therapy
ABX 12 (36.4) 3 (33.3) 488 (52.8)
Access 9 (27.3) 3 (33.3) 189 (20.5)
Chemo 9 (27.3) 3 (33.3) 95 (10.3)
TPN 3 (9.1) 0 (0) 152 (16.5)
Lumens
1 8 (24.2) 3 (33.3) 448 (48.5)
2 19 (57.6) 5 (55.6) 390 (42.2)
3 6 (18.2) 1 (11.1) 86 (9.3)
Power-PICC
Yes 22 (66.7) 5 (55.6) 473 (51.2)
Tunneled PICC
Yes 0 (0) 0 (0) 12 (1.3)
French (gauge)
4 8 (24.2) 3 (33.3) 422 (45.7)
5 19 (57.6) 5 (55.6) 404 (43.7)
6 6 (18.2) 1 (11.1) 98 (10.6)
Admitting bed
section
ICU 3 (9.1) 1 (11.1) 113 (17.5)
Medical 20 (60.6) 7 (77.8) 516 (55.8)
NH 2 (6.1) 1 (11.1) 79 (8.6)
Surgery 7 (21.2) 0 (0) 154 (16.7)
Other 1 (3.0) 0 (0) 62 (6.7)
Insertion vein
Basilic 23 (69.7) 4 (44.4) 715 (77.4)
Brachial 7 (21.2) 3 (33.3) 138 (14.9)
Cephalic 3 (9.1) 2 (22.2) 53 (5.7)
Other 0 (0) 0 (0) 18 (2.0)
Insertion arm
Right 22 (66.7) 8 (88.9) 644 (69.7)
Left 11 (33.3) 1 (11.1) 280 (30.3)
Table 1 (Continued)
Variable
PICC-DVT
(N = 33)
LE DVT
(N = 9)
No DVT
(N = 924)
Time to
DVT (days)
16.5  17.1 10.7  10.2 NA
PICC, peripherally inserted central catheter; DVT, deep vein throm-
bosis; LE DVT, lower extremity DVT; LOS, length of stay; ICU,
intensive care unit; CLABSI, central line-associated bloodstream
infection; IR, interventional radiology; ABX, antibiotics; Chemo,
chemotherapy; TPN, total parenteral nutrition; NH, nursing home;
NA, not applicable.
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lier time-to-event in patients with 5-Fr and 6-Fr PICCs
compared with 4-Fr PICCs.
Discussion
In this retrospective cohort study of a representative
group of consecutively hospitalized Veterans who under-
went PICC placement, we found that a cancer diagnosis
in the past 6 months and catheter gauge were the strong-
est predictors of PICC-DVT after adjustment for other
patient-, provider- and device-specific factors. The rela-
tionship between cancer and thrombosis persisted despite
inclusion of characteristics often cited as being associated
with DVT (e.g. prior surgery or prior VTE) and receipt
of pharmacologic DVT prophylaxis by most patients.
Additionally, 5-Fr and 6-Fr PICCs showed an earlier time
to DVT, suggesting an accelerated course towards throm-
bosis in patients who received these larger devices. These
findings question the wisdom of the use of PICCs in
patients with cancer and the use of devices of greater
gauge, as their thrombogenicity may outweigh presumed
benefits, especially among patients with malignancies.
The link between cancer and thrombosis was estab-
lished centuries ago [20]. Venous thromboembolism is a
common, costly and often morbid development in
patients with cancer. In fact, the development of throm-
bosis among patients with cancer is often an ominous
finding, as studies suggest that cancer patients who
experience thrombosis have a higher mortality rate than
those who do not [21–23]. Indeed, many of these deaths
may be due to fatal VTE, including pulmonary embolism.
However, some of these events may also reflect underlying
tumor biology, as activation of the coagulation cascade
and thrombin generation are often cited as mechanisms
by which tumor propagation may occur [24,25]. It is thus
not uncommon for malignancies to declare themselves
first with thromboses; in fact, up to 10% of patients with
so-called idiopathic or unprovoked thromboses ultimately
develop cancer on long-term follow-up [26].
Thrombotic events in cancer patients are often also
related to, or triggered by vascular access devices [13,27–
29]. With the growing use of PICCs among patients with
cancer, the burden of PICC-DVT is becoming more appar-
ent, as some studies report thrombosis rates as high as
30% with these devices [3]. Often, many of these events
remain clinically silent. In a recent randomized controlled
clinical trial that used screening ultrasound to detect
PICC-DVT, up to 75% of patients with catheters were
Table 3 Bivariable (unadjusted) analysis of risk factors associated
with PICC-DVT
Variable
Odds
ratio
95%
Confidence
interval P -value
Age 0.988 0.967 1.009 0.27
Acute LOS 1.019 0.999 1.040 0.07
ICU LOS 1.000 0.987 1.013 0.95
Cancer 2.300 1.120 4.410 0.01
Prior surgery (> 1 h) 0.984 0.489 1.982 0.97
Prior PICCs 1.181 0.780 1.789 0.43
No. of insertion attempts 1.126 0.804 1.578 0.49
Adjustments during insertion
Yes 0.619 0.255 1.502 0.29
Number of adjustments 0.588 0.304 1.136 0.11
Duration of PICC
use (days)
1.007 0.998 1.016 0.15
Operator
IR 2.421 1.240 4.727 0.01
PICC nurse 1 Ref Ref
Therapy
ABX 1 Ref Ref
Access 2.066 0.910 4.688 0.08
Chemo 4.109 1.784 9.468 0.001
TPN 0.642 0.180 2.288 0.49
Lumens
1 1 Ref Ref
2 2.506 1.220 5.149 0.01
3 3.315 1.243 8.840 0.02
Power-PICC
Yes 1.716 0.901 3.269 0.10
French (gauge)
4 1 Ref Ref
5 2.279 1.109 4.682 0.03
6 2.740 1.030 7.291 0.04
Admitting bed section
ICU 0.750 0.256 2.198 0.60
Surgery 0.963 0.410 2.265 0.93
Other 1 Ref Ref
Vein of insertion
Cephalic 2.221 0.839 5.877 0.11
Other 1 Ref Ref
Arm of insertion
Right 1 Ref Ref
Left 0.920 0.478 1.772 0.80
PICC, peripherally inserted central catheter; LOS, length of stay;
ICU, intensive care unit; DVT, deep vein thrombosis; IR, interven-
tional radiology; ABX, antibiotics; Chemo, chemotherapy; TPN,
total parenteral nutrition; Ref, reference group. Bold indicates statis-
tically significant result.
Table 2 Types of cancers among patients with PICC-DVT
Type of malignancy* Number of cases
None 21
Gastrointestinal malignancies
Esophagus 4
Stomach 2
Colon 1
Respiratory/upper airway
Larynx 2
Hypopharyngeal/tracheal 3
Genitourinary
Prostate 1
Testicular 1
Hematologic
Leukemia 5
Lymphoma 3
PICC, peripherally inserted central catheter; DVT, deep vein throm-
bosis. *As identified by ICD-9 Code.
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found to have thrombosis, with the majority of events
occurring in patients with cancer. Despite this high event
rate, only 4% of patients with image-confirmed thrombosis
developed clinical symptoms [30]. This finding is important
because some suggest that long-term pharmacological
DVT prophylaxis be routinely implemented in patients
with cancer to offset thrombosis. To date, however, several
systematic reviews and meta-analyses of the literature have
found no benefit associated with this approach [31–33]. A
recent Cochrane update echoed these findings, noting no
benefit even for asymptomatic thrombosis in this subset
[34]. Indeed, in our study, PICC-DVT occurred despite
high rates of DVT prophylaxis given the largely hospital-
ized cohort.
Uniquely, we also found that some thrombotic events
occurred in the lower, not just the upper, extremities. This
finding echoes early results of our larger, ongoing study of
52 989 hospitalized patients, where we found that PICC
presence by hospital day 2 was associated with a signifi-
cantly increased risk of not only upper- but also lower-
extremity DVT in patients with and without cancer
(OR=3.1 [95% CI 1.3–7.5]) [35]. Although we are not able
to mechanistically explain this observation, it is possible
that the insertion or presence of a PICC can result in endo-
thelial damage, vascular reactivity and up-regulated coagu-
lation. These changes may predispose towards a greater
overall risk of thrombosis that extends beyond the vascular
bed of the PICC itself. Studies that measure systemic mark-
ers of coagulation (e.g. D-dimer) in the presence of PICCs
may shed more light on this association.
Our findings regarding the association between PICC
gauge and greater risk of PICC-DVT are in accord with
the published evidence [14,15]. Uniquely, however, we
observed that patients with 5-Fr and 6-Fr devices are not
only at greater risk, but also develop thrombosis earlier
compared with those with 4-Fr devices. This finding is
novel and important because many multi-lumen PICCs
are available only in larger sizes and clinicians typically
only consider the number of lumens, not catheter size,
when ordering PICCs. The interaction between number of
lumens and thrombosis is thus likely to be confounded by
PICC gauge, suggesting that better delineation of this
relationship for front-line providers is necessary. Given
what is known, dual-lumen 4-Fr PICCs may offer the
best option for venous access and therapies from a com-
plication perspective when feasible [12,36].
As many patients with cancer require multi-lumen (e.g.
greater gauge) PICCs and no effective strategies to offset
thrombosis risk exist, what can providers do to prevent
PICC-DVT in this population? One approach is to simply
consider alternative vascular access devices for this subset.
Patients with malignancies often require longer-term
venous access for parenteral hydration, nutrition, blood
products and antimicrobials, in addition to chemotherapy
and laboratory draws [37,38]. While PICCs are appealing
because they can be safely placed in those with thrombocy-
topenia or bleeding diathesis [39], these benefits may be out-
weighed by the associated thrombosis and infection burden
[19,40]. Because other, potentially less thrombogenic,
options (e.g. infusion ports and tunneled catheters) are
available for venous access and some patients may not
require central venous access for delivery of irritants or ves-
icants, the ‘reflexive’ use of PICCs should be reconsidered
in this population. The use of midlines (devices that termi-
nate in arm veins as opposed to central chest veins) may
also prove useful in this subset if short-term administration
of non-vesicant or irritant substances is being considered
[41]. At the very least, this study and the available evidence
call for a mindful approach when selecting PICCs as the
vascular device of choice in patients with malignancies [42].
Our study has important limitations. First, our analysis
was conducted in an almost exclusively male population
at a single academic VA medical center, limiting general-
izability to dissimilar populations. Second, although
enhanced by combining medical record review and
administrative data, our ability to draw inferences is lim-
ited by available covariates owing to the retrospective
design of this study and the specific inclusion of popula-
tions who had complete data. It is therefore important to
note that information or selection biases may have influ-
enced our findings. Third, we included both upper and
lower-extremity thromboses when defining PICC-DVT;
Table 4 Multivariable (adjusted) analysis of risk factors associated with PICC-DVT
Variable
Logistic regression Cox proportional hazards
Odds
ratio Confidence interval P -value
Hazard
ratio Confidence interval P -value
Cancer 1.953 1.014 3.761 0.05 1.896 0.980 3.667 0.06
Prior surgery (> 1 h) 0.883 0.421 1.851 0.74 0.959 0.467 1.967 0.91
Prior VTE 1.427 0.305 6.682 0.65 1.050 0.217 5.074 0.95
French (gauge)
4 1 Ref Ref 1 Ref Ref
5 1.890 0.889 4.018 0.10 2.211 1.040 4.699 0.04
6 2.454 0.880 6.842 0.09 3.555 1.309 9.659 0.01
PICC, peripherally inserted central catheter; DVT, deep vein thrombosis; VTE, venous thromboembolism; IR, interventional radiology; ABX,
antibiotics; Chemo, chemotherapy; TPN, total parenteral nutrition; Ref, reference group. Bold indicates statistically significant result.
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although some may consider this inappropriate, this
approach has been used extensively in the VTE literature
to define thrombotic risk and is more reflective of the
problems associated with these devices [8,9,17]. Fourth,
we are unable to separate the incremental thrombotic
burden posed by a PICC from that of an underlying can-
cer when these coexisted. However, as our symptomatic
PICC-DVT rates parallel those of the published literature,
our results appear to accurately reflect the interplay
between these two factors and thus carry the same clinical
implications.
These limitations notwithstanding, our study has impor-
tant strengths, including a large sample size and the ability
to track outcomes over time given the integrated nature of
the VA healthcare system. Furthermore, our results clearly
have important clinical care and policy implications and
suggest that a recent diagnosis of cancer should prompt
consideration of non-PICC-based modalities for venous
access. Additionally, whenever considered absolutely neces-
sary, devices with the least number of lumens and smallest
gauge should be considered [36]. Finally, our study is
strengthened by the fact that we scientifically selected cova-
riates for inclusion in our multivariable models known to
influence PICC-DVT, increasing the applicability and rele-
vance of our results to clinical practice.
In conclusion, we found that patients with a recent
diagnosis of cancer and those who receive greater gauge
PICCs are at significant risk of PICC-DVT. Policies and
procedural oversights that restrict the use of this device
for vascular access and encourage mindfulness when it
comes to insertion of PICCs in this population are war-
ranted.
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